A combination of pirfenidone and TGF-β inhibition mitigates cystic echinococcosis-associated hepatic injury

Parasitology. 2021 Jun;148(7):767-778. doi: 10.1017/S0031182021000287. Epub 2021 Feb 15.

Abstract

Cystic echinococcosis (CE) occurs in the intermediate host's liver, assuming a bladder-like structure surrounded by the host-derived collagen capsule mainly derived from activated hepatic stellate cells (HSCs). However, the effect of CE on liver natural killer (NK) cells and the potential of transforming growth factor-β (TGF-β) signalling inhibition on alleviating CE-related liver damage remain to be explored. Here, by using the CE-mouse model, we revealed that the inhibitory receptors on the surface of liver NK cells were up-regulated, whereas the activating receptors were down-regulated over time. TGF-β1 secretion was elevated in liver tissues and mainly derived from macrophages. A combination of TGF-β signalling inhibitors SB525334 and pirfenidone could reduce the expression of TGF-β1 signalling pathway-related proteins and collagen production. Based on the secretion of TGF-β1, only the pirfenidone group showed a depressing effect. Also, the combination of SB525334 and pirfenidone exhibited a higher potential in effectively alleviating the senescence of the hepatocytes and restoring liver function. Together, TGF-β1 may be a potential target for the treatment of CE-associated liver fibrosis.

Keywords: Cystic echinococcosis; Echinococcus granulosus; hepatocyte senescence; liver fibrosis; natural killer cell.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Echinococcosis, Hepatic / drug therapy*
  • Imidazoles / pharmacology*
  • Liver
  • Mice
  • Pyridones / pharmacology*
  • Quinoxalines / pharmacology*
  • Transforming Growth Factor beta1 / antagonists & inhibitors*

Substances

  • 6-(2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline
  • Imidazoles
  • Pyridones
  • Quinoxalines
  • Transforming Growth Factor beta1
  • pirfenidone

Associated data

  • ChiCTR/ChiCTR1900024122